Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a

Pediatrics

Volumn 103, Issue 6 I, 1999, Pages 1145-1149

  Kaban, Leonard B ^a   Mulliken, John B ^b   Ezekowitz, R Alan ^a   Ebb, David ^c   Smith, Peter S ^c   Folkman, Judah ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Giant cell tumor of mandible; Interferon alfa 2a

Indexed keywords

ALPHA2 INTERFERON; BASIC FIBROBLAST GROWTH FACTOR;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE OVEREXPRESSION; GIANT CELL TUMOR; HEMANGIOMA; HUMAN; MANDIBLE TUMOR; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RECURRENT CANCER; TREATMENT OUTCOME; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; FEMALE; FIBROBLAST GROWTH FACTOR 2; GIANT CELL TUMORS; HUMANS; INTERFERON ALFA-2A; MANDIBLE; MANDIBULAR NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033041884     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.103.6.1145     Document Type: Article

References (48)

1. Brouty-Boye D, Zetter B. Inhibition of cell motility by interferon. Science. 1980;208:516-518
2. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155-5161
3. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst. 1989;81:497-502
4. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med. 1989;320:1197-1200
5. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med. 1989;320:1211-1212
6. Orchard PJ, Smith CM III, Woods WG, Day DL, Dehner LP, Shapiro R. Treatment of haemangioendotheliomas with alpha interferon. Lancet. 1989;2:565-567
7. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326: 1456-1463. (Erratum [1994]. N Engl J Med. 1994:330:300)
8. Loughnan MS, Elder J, Kemp A. Treatment of a massive orbital capillary hemangioma with interferon alfa-2b: short-term results. Arch Ophthalmol. 1992;110:1366-1367
9. Hatley RM, Sabio H, Howell CG, Flickinger F, Parrish RA. Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with alpha-interferon. J Pediatr Surg. 1993;28:1356-1359
10. White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF, Yu A. Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr. 1991;118:59-66
11. Blei F, Orlow SJ, Geronemus RG. Interferon alfa-2a therapy for extensive perianal and lower extremity hemangioma. J Am Acad Dermatol. 1993;29:98-99
12. Ricketts RR, Hately RM, Corden BJ, Sabio H, Howell CG. Interferon alfa-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg. 1994;219:605-614
13. Ohlms LA, Jones DT, McGill TJI, Healy GB. Interferon alfa-2a therapy for airway hemangiomas. Ann Otol Rhinol Laryngol. 1994;103:1-8
14. MacArthur CJ, Senders CW, Katz J. The use of interferon alfa-2a for life-threatening hemangiomas. Arch Head Neck Surg. 1995;121:690-693
15. Mulliken JB, Boon LM, Takahashi K, Ohlms LA, Folkman J, Ezekowitz RAB. Pharmacologic therapy for endangering hemangiomas. Curr Opin Dermatol 1995;2:109-113
16. Deb G, Donfrancesco A, De Sio L, Standoli L. Treatment of hemangiomas of infancy and babies with interferon alfa-2a: preliminary results. Int J Pediatr/Oncol. 1996;3:109-113
17. Boon LM, Burrows PE, Paltiel HJ, et al. Hepatic vascular anomalies in infancy: a twenty-seven year experience. J Pediatr. 1996;129:346-354
18. Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon alfa-2b. J Pediatr Hematol/Oncol. 1997;19: 237-244
19. Folkman J, Mulliken JB, Ezekowitz RAB. Antiangiogenic therapy of haemangiomas with interferon A. In: Stuart-Harris R, Penny R, eds. The Clinical Applications of the Interferons. London, England: Chapman & Hall Medical; 1997:255-265
20. Sarkar M, Mulliken JB, Kozakewich HPW, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg. 1997;100:1377-1386
21. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132:527-530
22. Takahashi K, Mulliken JB, Kozakewich HPW, Rogers RA, Folkman J, Ezekowitz RAB. Cellular markers that distinguish the phase of hemangioma during infancy and childhood. J Clin Invest. 1994;93:2357-2364
23. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757-1763
24. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994;86:356-361
25. Bielenberg DR, Bucana CD, Sanchez R, Mulliken JB, Folkman J, Fidler IJ. Progressive growth of infantile cutaneous hemangiomas is directly correlated with angiogenesis and hyperplasia of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, interferon beta. Int J Oncol. 1999;14:401-408
26. Chuong R, Kaban LB. Diagnosis and treatment of jaw tumors in children. J Oral Maxillofac Surg. 1985;43:323-332
27. Padwa BL, Denhart B, Kaban, LB. Aneurysmal bone cyst plus. J Oral Maxillofac Surg. 1997;55:1144-1151
28. Kaban LB. Aggressive jaw tumors in children. Oral Maxillofac Surg Clin North Am. 1993;5:249-266
29. Chuong R, Kaban LB, Kozakewich H, et al. Central giant cell lesions of the jaws: a clinicopathologic study. J Oral Maxillofac Surg. 1986;44: 708-713
30. Ficarra G, Kaban LB, Hansen LS. Central giant cell lesions of the maxilla and mandible: a clinicopathologic study. Oral Surg. 1987;64:44-49
31. Curtis ML, Hatfield CF, Pierce JM. A destructive giant cell lesion of the mandible. J Oral Surg. 1973;31:705-709
32. Granite EL, Aronoff AK, Gold L. Central giant cell reparative granuloma of the mandible: a case report. Oral Surg. 1982;53:241-246
33. Leban SG, Lepore H, Stratigos GT, et al. The giant cell lesion of the jaws: neoplastic or reparative? J Oral Surg. 1971;29:398-404
34. Quick CA, Anderson R, Stool S. Giant cell tumors of the maxilla in children. Laryngoscope. 1980;90:784-791
35. Small GS, Rowe NH. A true "giant cell tumor" in the mandible? J Oral Surg. 1975;33:296-301
36. Terry BC, Jacoway JR. Management of central giant cell lesions. An alternative to surgical therapy. Oral Maxillofac Surg Clin North Am. 1994;6:579-600
37. Harris M. Central giant cell granulomas of the jaws regress with calcitonin therapy. Br J Oral Maxillofac Surg. 1993;31:89-94
38. Pogrel MAP, Harris ST, Regezi J, Goldring S. Calcitonin therapy for central giant cell granulomas J Oral Maxillofac Surg. 1997;55(suppl):38. Abstract
39. Kazanjian VH. Spontaneous regeneration of bone following excision of section of the mandible. Am J Orthod. 1946;32:242-248
40. Shuker S. Spontaneous regeneration of the mandible in a child. J Maxillofac Surg. 1985;13:70-73
41. Nagase M, Ueda K, Susuki, et al. Spontaneous regeneration of the condyle following hemimandibulectomy by disarticulation. J Oral Maxillofac Surg. 1985;43:218-220
42. Adekeye EO. Rapid bone regeneration subsequent to subtotal mandibulectomy. Report of an unusual case. Oral Surg Oral Med Oral Pathol. 1997;44:521-526
43. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 1995;92: 4562-4566
44. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary human tumors. Nature Med. 1996;2:689-692
45. Boehm T, Folkman J, Browder T, O'Reilly MS. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-407
46. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364
47. Kaiser U, Neumann K, Havemann K. Generalized giant-cell tumour of bone: successful treatment of pulmonary metastases with interferon alpha, a case report. J Cancer Res Clin Oncol. 1993;119:301-303
48. Strander H, Boethius J, Erhardt K, et al. Does successful interferon treatment of tumor patients require life-long treatment? J Interferon Res. 1987;7:619-626